[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516513":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":240,"collaborators":24,"id":242,"slug":243,"hasResults":244,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":24,"eligibilityCriteria":248,"healthyVolunteers":244,"sex":249,"minAge":250,"maxAge":24,"enrollmentInfo":251,"targetDuration":24,"studyType":254,"phases":255,"briefSummary":258,"conditions":259,"keywords":264,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Module 1: AZD5863 Monotherapy Intravenous (IV)","EXPERIMENTAL","Module 1: AZD5863 Intravenous (IV) Monotherapy",[13],"Drug: AZD5863",{"label":15,"type":10,"description":16,"interventionNames":17},"Module 2: AZD5863 Monotherapy Subcutaneous (SC)","Module 2: AZD5863 Subcutaneous (SC) Monotherapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","AZD5863","T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[32,46,55,64,74,79,86,96,104,114,122,130,140,148,156,165,170,175,180,190,198,206,216,224,232],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":24},"Research Site","RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-81.65565,30.33218,{"lat":44,"lon":43},{"facility":33,"status":34,"city":47,"state":48,"zip":49,"country":38,"countryCode":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":24},"Rochester","Minnesota","55905",{"type":41,"coordinates":51},[52,53],-92.4699,44.02163,{"lat":53,"lon":52},{"facility":33,"status":56,"city":57,"state":57,"zip":58,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":63,"contacts":24},"WITHDRAWN","New York","10065",{"type":41,"coordinates":60},[61,62],-74.00597,40.71427,{"lat":62,"lon":61},{"facility":33,"status":34,"city":65,"state":24,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":24},"Beijing","100142","China","CN",{"type":41,"coordinates":70},[71,72],116.39723,39.9075,{"lat":72,"lon":71},{"facility":33,"status":34,"city":65,"state":24,"zip":75,"country":67,"countryCode":68,"cosmosGeoPoint":76,"geoPoint":78,"contacts":24},"101199",{"type":41,"coordinates":77},[71,72],{"lat":72,"lon":71},{"facility":33,"status":34,"city":80,"state":24,"zip":24,"country":67,"countryCode":68,"cosmosGeoPoint":81,"geoPoint":85,"contacts":24},"Shandong",{"type":41,"coordinates":82},[83,84],120.48412,40.28464,{"lat":84,"lon":83},{"facility":33,"status":34,"city":87,"state":24,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":24},"Toulouse","31059","France","FR",{"type":41,"coordinates":92},[93,94],1.44367,43.60426,{"lat":94,"lon":93},{"facility":33,"status":34,"city":97,"state":24,"zip":98,"country":89,"countryCode":90,"cosmosGeoPoint":99,"geoPoint":103,"contacts":24},"Villejuif","94805",{"type":41,"coordinates":100},[101,102],2.35992,48.7939,{"lat":102,"lon":101},{"facility":33,"status":34,"city":105,"state":24,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":24},"Chūōku","104-0045","Japan","JP",{"type":41,"coordinates":110},[111,112],130.67068,33.63867,{"lat":112,"lon":111},{"facility":33,"status":34,"city":115,"state":24,"zip":116,"country":107,"countryCode":108,"cosmosGeoPoint":117,"geoPoint":121,"contacts":24},"Kashiwa","227-8577",{"type":41,"coordinates":118},[119,120],139.97732,35.86224,{"lat":120,"lon":119},{"facility":33,"status":34,"city":123,"state":24,"zip":124,"country":107,"countryCode":108,"cosmosGeoPoint":125,"geoPoint":129,"contacts":24},"Kōtoku","135-8550",{"type":41,"coordinates":126},[127,128],143.14297,42.50417,{"lat":128,"lon":127},{"facility":33,"status":34,"city":131,"state":24,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":24},"Amsterdam","1081 HV","Netherlands","NL",{"type":41,"coordinates":136},[137,138],4.88969,52.37403,{"lat":138,"lon":137},{"facility":33,"status":34,"city":141,"state":24,"zip":142,"country":133,"countryCode":134,"cosmosGeoPoint":143,"geoPoint":147,"contacts":24},"Groningen","9713 GZ",{"type":41,"coordinates":144},[145,146],6.56667,53.21917,{"lat":146,"lon":145},{"facility":33,"status":34,"city":149,"state":24,"zip":150,"country":133,"countryCode":134,"cosmosGeoPoint":151,"geoPoint":155,"contacts":24},"Rotterdam","3015 GD",{"type":41,"coordinates":152},[153,154],4.47917,51.9225,{"lat":154,"lon":153},{"facility":33,"status":34,"city":157,"state":24,"zip":158,"country":159,"countryCode":24,"cosmosGeoPoint":160,"geoPoint":164,"contacts":24},"Seoul","03080","South Korea",{"type":41,"coordinates":161},[162,163],126.9784,37.566,{"lat":163,"lon":162},{"facility":33,"status":34,"city":157,"state":24,"zip":166,"country":159,"countryCode":24,"cosmosGeoPoint":167,"geoPoint":169,"contacts":24},"03722",{"type":41,"coordinates":168},[162,163],{"lat":163,"lon":162},{"facility":33,"status":34,"city":157,"state":24,"zip":171,"country":159,"countryCode":24,"cosmosGeoPoint":172,"geoPoint":174,"contacts":24},"05505",{"type":41,"coordinates":173},[162,163],{"lat":163,"lon":162},{"facility":33,"status":34,"city":157,"state":24,"zip":176,"country":159,"countryCode":24,"cosmosGeoPoint":177,"geoPoint":179,"contacts":24},"06351",{"type":41,"coordinates":178},[162,163],{"lat":163,"lon":162},{"facility":33,"status":34,"city":181,"state":24,"zip":182,"country":183,"countryCode":184,"cosmosGeoPoint":185,"geoPoint":189,"contacts":24},"Kaohsiung City","80756","Taiwan","TW",{"type":41,"coordinates":186},[187,188],120.31333,22.61626,{"lat":188,"lon":187},{"facility":33,"status":34,"city":191,"state":24,"zip":192,"country":183,"countryCode":184,"cosmosGeoPoint":193,"geoPoint":197,"contacts":24},"Tainan","70403",{"type":41,"coordinates":194},[195,196],120.21333,22.99083,{"lat":196,"lon":195},{"facility":33,"status":34,"city":199,"state":24,"zip":200,"country":183,"countryCode":184,"cosmosGeoPoint":201,"geoPoint":205,"contacts":24},"Taoyuan","00333",{"type":41,"coordinates":202},[203,204],121.29696,24.99368,{"lat":204,"lon":203},{"facility":33,"status":34,"city":207,"state":24,"zip":208,"country":209,"countryCode":210,"cosmosGeoPoint":211,"geoPoint":215,"contacts":24},"Dundee","DD1 9SY","United Kingdom","UK",{"type":41,"coordinates":212},[213,214],-2.97489,56.46913,{"lat":214,"lon":213},{"facility":33,"status":34,"city":217,"state":24,"zip":218,"country":209,"countryCode":210,"cosmosGeoPoint":219,"geoPoint":223,"contacts":24},"London","E1 1BB",{"type":41,"coordinates":220},[221,222],-0.12574,51.50853,{"lat":222,"lon":221},{"facility":33,"status":34,"city":225,"state":24,"zip":226,"country":209,"countryCode":210,"cosmosGeoPoint":227,"geoPoint":231,"contacts":24},"Metropolitan Borough of Wirral","CH63 4JY",{"type":41,"coordinates":228},[229,230],-3.10501,53.37616,{"lat":230,"lon":229},{"facility":33,"status":34,"city":233,"state":24,"zip":234,"country":209,"countryCode":210,"cosmosGeoPoint":235,"geoPoint":239,"contacts":24},"Oxford","OX3 7LE",{"type":41,"coordinates":236},[237,238],-1.25596,51.75222,{"lat":238,"lon":237},{"type":241,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100516513","phase-1-study-of-azd5863-in-adult-participants-with-advanced-or-metastatic-solid-tumors-100516513",false,"NCT06005493","Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","A Phase I\u002FII Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 at the time of signing the informed consent\n* Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening\n* Predicted life expectancy of ≥ 12 weeks\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol\n* Must have received at least one prior line of systemic therapy in the advanced\u002Fmetastatic setting\n\nKey Exclusion Criteria:\n\n* Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol\n* Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) \u002F macrophage activation syndrome (MAS)\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment\n* central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent\n* Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B\u002FC, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection\n* Cardiac conditions as defined by the protocol\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention\n* Participant requires chronic immunosuppressive therapy\n* Participants on anticoagulation therapy with long-acting anticoagulants or other class of anticoagulants at therapeutic doses","ALL","18 Years",{"count":252,"type":253},280,"ESTIMATED","INTERVENTIONAL",[256,257],"PHASE1","PHASE2","This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.",[260,261,262,263],"Gastric Cancer","Gastro-esophageal Junction Cancer","Pancreatic Ductal Adenocarcinoma","Esophageal Adenocarcinoma",[265,266,267,268,269,270,271,21],"CLDN18.2 \u002F Claudin 18.2","CD3","T cell-engaging bi-specific antibody","Gastric cancer","Gastro-esophageal junction cancer","Pancreatic ductal adenocarcinoma","Solid tumors","2026-02-23",{"date":274,"type":275},"2026-02-24","ACTUAL",{"date":277,"type":275},"2023-07-11",{"date":279,"type":253},"2027-07-16",{"name":5,"class":6},25]